3rd Nov 2006 16:41
Hikma Pharmaceuticals Plc03 November 2006 Section 198 Notification London, 3 November 2006 - On 2 November 2006, Hikma Pharmaceuticals PLC (LSE:HIK) (DIFX: HIK) ("the Company") received notification from The Capital GroupCompanies, Inc., pursuant to Section 198 Companies Act 1985, that at the closeof its business on 1 November 2006, The Capital Group Companies, Inc., onbehalf of its affiliates, including Capital Research and Management Company,had an interest in 10,223,003 ordinary shares of 10p each in the Company, which represents 6.097 per cent of the issued ordinary share capital of the Company,as follows: No. of shares Percent of ordinary shares outstanding The Capital GroupCompanies, Inc. 10,223,003 6.097%held as follows: Capital Research andManagement Company 10,223,003 6.097%of which: SMALLCAP World Fund,Inc. 5,069,153 3.023% New World Fund, Inc. 5,153,850 3.074% Registered holders:State Street Nominees Limited 5,069,153 Chase Nominees Limited 5,153,850 Total 10,223,003 - ENDS - Enquiries: Hikma Pharmaceuticals PLC +44 20 7399 2670Henry Knowles, Company SecretarySusan Ringdal, Investor Relations DirectorBrunswick Group LLP +44 20 7404 5959Jon Coles / Justine McIlroy / Alex Tweed About HikmaHikma Pharmaceuticals PLC is a multinational pharmaceutical group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: Generic, Branded and InjectablePharmaceuticals. Hikma's operations are based principally in the United States,the Middle East and North Africa ("MENA") region and Europe. In 2005, the Grouphad revenue of $262 million and profit attributable to shareholders of $44million. At 31 December 2005, the Group had over 1,800 employees. For news andother information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Hikma Pharmaceuticals